Cardiovascular Risk Assessment (ApoB & Lp(a))
Dr. Reddy explains that while most people know their LDL cholesterol, ApoB is a superior marker for cardiovascular risk. He uses an airport analogy: LDL-C measures passengers (cholesterol content), while ApoB measures planes (particle count). More planes (ApoB) mean more risk, regardless of passenger count. This is particularly crucial for individuals with metabolic disease or diabetes, where LDL-C can be misleadingly low despite high ApoB (LDL discordance). Additionally, Lp(a) is a genetically determined lipoprotein that behaves like LDL but is more dangerous due to its stickiness and inflammatory nature, leading to more plaque. It's often overlooked because there's currently no direct treatment for high Lp(a), but knowing its level helps categorize a patient's overall risk (low, medium, high) and informs the aggressiveness of other interventions. Since it's genetic, a single test is sufficient.
ApoB measures the number of atherogenic lipoprotein particles, which are directly responsible for delivering cholesterol into the artery walls, leading to plaque formation. Lp(a) is a modified LDL particle with an additional apolipoprotein(a) component, making it more prone to oxidation, inflammation, and deposition in arterial walls, contributing to accelerated atherosclerosis.
LDLC measures the amount of cholesterol inside the LDL particles. And APOB measures the number of particles themselves and that's a better predictor of heart disease risk.

